English
This article is from Annals of Indian Academy of Neurology , volume 16 . Abstract The cornerstone of diagnosis of Alzheimer's disease (AD) is still the clinical criteria for probable and possible AD established by the NINCDS-ADRDA Work Group in 1984, which had survived for over 27 years. However, with the increase in people's knowledge of clinical manifestations and biology of AD, this standard is gradually proving to be insufficient; the early diagnosis of AD is thus particularly important. Therefore, in 2011, the National Institute on Aging and the Alzheimer's Association revised the criteria and integrated biomarker evidence into it. Biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD. According to Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease, a qualified biomarker for AD should have the following abilities: It should detect a fundamental feature of neuropathology and be validated in neuropathologically confirmed cases, reliably with an sensitivity >80% for detecting AD and a specificity >80% for distinguishing other dementias; be reproducible and non-invasive; and be simple to p
Sign in with your free account to read, download EPUBs or listen.
Ebook · A literature review of AD7c-ntp as a biomarker for Alzheimer's disease. · Zhang, Jian, Shi, Shengliang · Internet Archive